Currently, there is an ongoing phase I trial evaluating a three-drug combination comprising azacitidine, APR-246, and venetoclax in TP53 mutated treatment-naive AML patients (NCT04214860); in addition, another multi-center, open-label, phase II clinical trial is assessing APR-246 in combination with azacitidine as maintenance therapy after allo-HSCT for patients with TP53 mutant AML or MDS (NCT03931291) [116,117,118]. The gene discussed is TP53; the disease is myelodysplastic syndrome.